OncoMatch/Clinical Trials/NCT05974774
Intermittent Androgen Deprivation Therapy in the Era of AR Pathway Inhibitors
Is NCT05974774 recruiting? Yes, currently enrolling (Jun 2026). This Phase 3 trial studies multiple treatments including iMAB and cMAB for prostate cancer.
Treatment: iMAB · cMAB — This study addresses the global topic of treatment optimization, i.e. achieving similar benefit while reducing the duration of treatment, hence hoping to decrease the burden of side-effects, improve quality-of life and reduce resource utilization. The primary goal of de-escalation is to investigate whether using an intermittent regime results in a similar OS to continuous treatment.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Prostate Cancer
Disease stage
Required: Stage MHNPC
Metastatic disease required
Patient treated with ADT and an ARPI for mHNPC for 6-12 months... Patients with synchronous or metachronous metastases, high volume/risk or low volume/risk who fulfil the criteria can be included.
Demographics
Prior therapy
Must have received: androgen deprivation therapy — mHNPC
Patient treated with ADT and an ARPI for mHNPC for 6-12 months
Must have received: androgen receptor pathway inhibitor — mHNPC
Patient treated with ADT and an ARPI for mHNPC for 6-12 months
Cannot have received: systemic anti-prostate cancer treatment not approved by EMA together with MAB
Patients who have received a systemic anti-prostate cancer treatment not approved by EMA together with MAB
Cannot have received: radical prostatectomy for M1 disease
Patients who have received...a radical prostatectomy for M1 disease
Cannot have received: bilateral orchiectomy
Patients who underwent or will undergo a bilateral orchiectomy
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT05974774 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior systemic anti-prostate cancer treatment not approved by EMA together with MAB, radical prostatectomy for M1 disease, bilateral orchiectomy disqualifies patients from enrollment.
What disease stage is eligible?
Stage MHNPC is required (metastatic disease required).
Is there an age limit?
Yes. Patients must be 100 years or younger.
Is this trial open to female patients?
No. This trial enrolls male patients only.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages